BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation

The main goal is to investigate whether beta cell mass is correlated to beta cell function after autologous faecal microbial transplantation (FMT) in patients with newly diagnosed type 1 diabetes

Inclusion Criteria:Previously participated in ENCAPSULATE-DM1 or FMT preserve-DM1 trialType 1 diabetes with the diagnosis being made in the last 4.5 yearsPresence of at least one autoantibody associated with type 1 diabetes (anti-GAD-65, anti-IA2, islet cell antibodies, insulin autoantibodies)Age ≥ 18 yearsBMI 18-30 kg/m2Insulin useExclusion Criteria:Inability to provide written informed consentOther medication use than insulinSmokingEvidence of compromised immunityPresence of a second autoimmune disease (other than type 1 diabetes); e.g. celiac disease, hyper- or hypothyroidism, inflammatory bowel disease. Vitiligo is allowed.Pregnancy or the wish to become pregnant within 1 month after the studyBreastfeedingLiver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal rangeRenal disease defined as MDRD < 40 ml/min/1.73 m²